Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study

No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ)...

Descripción completa

Detalles Bibliográficos
Autores principales: Dabbous, Hany M., Abd-Elsalam, Sherief, El-Sayed, Manal H., Sherief, Ahmed F., Ebeid, Fatma F. S., El Ghafar, Mohamed Samir Abd, Soliman, Shaimaa, Elbahnasawy, Mohamed, Badawi, Rehab, Tageldin, Mohamed Awad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829645/
https://www.ncbi.nlm.nih.gov/pubmed/33492523
http://dx.doi.org/10.1007/s00705-021-04956-9
_version_ 1783641218849177600
author Dabbous, Hany M.
Abd-Elsalam, Sherief
El-Sayed, Manal H.
Sherief, Ahmed F.
Ebeid, Fatma F. S.
El Ghafar, Mohamed Samir Abd
Soliman, Shaimaa
Elbahnasawy, Mohamed
Badawi, Rehab
Tageldin, Mohamed Awad
author_facet Dabbous, Hany M.
Abd-Elsalam, Sherief
El-Sayed, Manal H.
Sherief, Ahmed F.
Ebeid, Fatma F. S.
El Ghafar, Mohamed Samir Abd
Soliman, Shaimaa
Elbahnasawy, Mohamed
Badawi, Rehab
Tageldin, Mohamed Awad
author_sort Dabbous, Hany M.
collection PubMed
description No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation. ClinicalTrials.gov Identifier NCT04351295.
format Online
Article
Text
id pubmed-7829645
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-78296452021-01-25 Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study Dabbous, Hany M. Abd-Elsalam, Sherief El-Sayed, Manal H. Sherief, Ahmed F. Ebeid, Fatma F. S. El Ghafar, Mohamed Samir Abd Soliman, Shaimaa Elbahnasawy, Mohamed Badawi, Rehab Tageldin, Mohamed Awad Arch Virol Brief Report No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation. ClinicalTrials.gov Identifier NCT04351295. Springer Vienna 2021-01-25 /pmc/articles/PMC7829645/ /pubmed/33492523 http://dx.doi.org/10.1007/s00705-021-04956-9 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH, AT part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Brief Report
Dabbous, Hany M.
Abd-Elsalam, Sherief
El-Sayed, Manal H.
Sherief, Ahmed F.
Ebeid, Fatma F. S.
El Ghafar, Mohamed Samir Abd
Soliman, Shaimaa
Elbahnasawy, Mohamed
Badawi, Rehab
Tageldin, Mohamed Awad
Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
title Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
title_full Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
title_fullStr Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
title_full_unstemmed Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
title_short Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
title_sort efficacy of favipiravir in covid-19 treatment: a multi-center randomized study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829645/
https://www.ncbi.nlm.nih.gov/pubmed/33492523
http://dx.doi.org/10.1007/s00705-021-04956-9
work_keys_str_mv AT dabboushanym efficacyoffavipiravirincovid19treatmentamulticenterrandomizedstudy
AT abdelsalamsherief efficacyoffavipiravirincovid19treatmentamulticenterrandomizedstudy
AT elsayedmanalh efficacyoffavipiravirincovid19treatmentamulticenterrandomizedstudy
AT sheriefahmedf efficacyoffavipiravirincovid19treatmentamulticenterrandomizedstudy
AT ebeidfatmafs efficacyoffavipiravirincovid19treatmentamulticenterrandomizedstudy
AT elghafarmohamedsamirabd efficacyoffavipiravirincovid19treatmentamulticenterrandomizedstudy
AT solimanshaimaa efficacyoffavipiravirincovid19treatmentamulticenterrandomizedstudy
AT elbahnasawymohamed efficacyoffavipiravirincovid19treatmentamulticenterrandomizedstudy
AT badawirehab efficacyoffavipiravirincovid19treatmentamulticenterrandomizedstudy
AT tageldinmohamedawad efficacyoffavipiravirincovid19treatmentamulticenterrandomizedstudy

Ejemplares similares